Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$113.43
+1.8%
$105.14
$76.53
$131.49
$27.27B1.29942,899 shs207,525 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$15.04
+0.7%
$13.89
$8.02
$15.78
$7.47B1.675.01 million shs737,338 shs
Insmed, Inc. stock logo
INSM
Insmed
$102.38
-0.5%
$87.63
$60.40
$106.83
$19.42B0.92.29 million shs508,483 shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$295.75
+0.1%
$250.96
$154.43
$300.00
$32.41B0.28436,297 shs125,835 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
+2.32%+0.71%+4.61%-3.07%+29.46%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.05%+2.43%+11.15%+62.66%+17.01%
Insmed, Inc. stock logo
INSM
Insmed
+0.14%+0.05%+0.23%+45.37%+34.92%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+1.25%+9.60%+19.63%+18.65%+29,558,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
1.429 of 5 stars
3.42.00.00.01.00.80.0
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.079 of 5 stars
1.41.00.00.33.41.71.3
Insmed, Inc. stock logo
INSM
Insmed
3.9998 of 5 stars
2.54.00.04.33.01.70.6
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
1.4736 of 5 stars
2.50.00.00.02.41.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.83
Moderate Buy$136.5820.41% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.88
Moderate Buy$16.006.42% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$109.206.66% Upside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
3.00
Buy$327.5610.75% Upside

Current Analyst Ratings Breakdown

Latest ELAN, ONC, BNTX, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$119.00 ➝ $130.00
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$18.00
7/17/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$102.00 ➝ $108.00
7/17/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$321.00 ➝ $345.00
7/16/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$127.00 ➝ $126.00
7/16/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$311.00 ➝ $349.00
7/10/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$132.00 ➝ $133.00
7/8/2025
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
6/27/2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.00
(Data available from 7/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$2.75B9.93N/AN/A$87.61 per share1.29
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.68$2.31 per share6.51$12.33 per share1.22
Insmed, Inc. stock logo
INSM
Insmed
$363.71M53.40N/AN/A$1.60 per share63.99
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$4.18B7.76N/AN/A$34.10 per share8.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$719.92M-$3.40N/AN/AN/A-27.37%-3.94%-3.41%8/4/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7420.3316.892.868.43%7.54%3.57%8/7/2025 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-$644.79M-$3.72N/A416.55N/A-9.40%-7.55%-4.42%8/6/2025 (Confirmed)

Latest ELAN, ONC, BNTX, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.31N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989N/AN/AN/A$1.19 billionN/A
8/4/2025Q2 2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.38N/AN/AN/A$161.26 millionN/A
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$1.531.35%N/AN/A N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
10.18
10.02
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.05
1.96
1.71

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Insmed, Inc. stock logo
INSM
Insmed
N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Insmed, Inc. stock logo
INSM
Insmed
3.00%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6,772240.39 million194.24 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
11,000109.60 million102.34 millionN/A

Recent News About These Companies

BeOne Medicines (NASDAQ:ONC) Price Target Raised to $349.00
NICE moves fast on Brukinsa in MCL

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$113.42 +1.99 (+1.78%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$15.04 +0.11 (+0.70%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Insmed stock logo

Insmed NASDAQ:INSM

$102.38 -0.54 (-0.52%)
As of 11:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$295.75 +0.16 (+0.05%)
As of 11:26 AM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.